Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Joanna M. Rhodes, Naleen Raj Bhandari, Manoj Khanal, Dan He, Sarang Abhyankar, John M. Pagel, Lisa M. Hess, Alan P Skarbnik

Blood (2024) 144 (Supplement 1): 5114.

https://doi.org/10.1182/blood-2024-193673

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Blood (2024) 144 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2024-205668

Published: 2024

Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Blood (2024) 144 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2024-200701

Published: 2024

Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Blood (2024) 144 (Supplement 1): 3132.1.

https://doi.org/10.1182/blood-2024-194909

Published: 2024

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Blood (2024) 144 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2024-205223

Published: 2024

Journal Articles

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Alan P. Skarbnik, Franklin L. Chen, Luke Mountjoy, Zaw Win Myint, Patricia A. Young, Andrew R. Whiteley, Steven Novick, Jennifer Su, Qingxi Wang, Kevin Romanko, Xi-De Wang, Yejia Li, Shulin Zhong, Liping Song, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 12059–12060.

https://doi.org/10.1182/blood-2022-164746

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik

Blood (2022) 140 (Supplement 1): 12108–12109.

https://doi.org/10.1182/blood-2022-157596

Published: 2022

Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Blood (2021) 137 (20): 2817–2826.

https://doi.org/10.1182/blood.2020007376

Published: 2021

Includes: Supplemental data

Journal Articles

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon, Jorge J. Castillo, Alan P. Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang

Blood (2020) 135 (21): 1912–1915.

https://doi.org/10.1182/blood.2020006288

Published: 2020

Journal Articles

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Blood (2018) 132 (23): 2446–2455.

https://doi.org/10.1182/blood-2018-05-850461

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Alan P Skarbnik, MD, Mary E Dilorenzo, APN, Michele Simone, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Maribel Pereiras, Pharm D, Tracy Andrews, MSc, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2018-99-113639

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Blood (2018) 132 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2018-99-118159

Published: 2018

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

NARROW

Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only